April 25th 2024
The second in our 3-part quiz series based on the NLA's 2024 update to their 2019 scientific statement on use of lipoprotein(a) in clinical practice focuses on recommendations for patients.
Despite Advances, Room for Improvement in Anticoagulation Exists for Older Adults
November 21st 2022An analysis of data from Medicare beneficiaries receiving treatment over a decade-long period provides a snapshot of oral anticoagulation initiation and nonadherence among older patients with atrial fibrillation in the US.
Almost 1 in 3 High-Risk AFib Patients Not Receiving Anticoagulation
November 17th 2022Using data from 88 medical centers across the US, new data is providing clinicians with an overview of contemporary trends in DOAC and warfarin use in adult patients with nonvalvular atrial fibrillation at high risk for stroke over the past decade.
Study Proves Feasibility of Entirely Remote Management of Hypertension, Cholesterol Disorders
November 10th 2022A 10,000-person study provides insight into the feasibility and effectiveness of participation an entirely remote hypertension and lipid management program in a diverse health care network.
SPORT: Supplements Fail to Lower LDL-C in Primary Prevention Population
November 8th 2022Erin Michos, MD, provides further insight in an on-site interview AHA 22 related to results of the SPORT trial, which provide direct comparative insights into the impact of several dietary supplements and placebo therapy relative to low-dose statin therapy in a primary prevention cohort.
Edoxaban Could Safely Reduce Risk of Thromboembolism in Pediatric Patient Populations
November 4th 2022Data from a phase 3 trial presented at AHA 22 suggests use of edoxaban could be a safe and effective method for reducing risk of thromboembolism in pediatric patients with cardiovascular disease considered to be at increased risk of thrombosis.
Minority Patients with AFib Less Likely to Receive Oral Anticoagulation than White Counterparts
October 28th 2022An analysis of the GWTG-Atrial Fibrillation Registry data suggests Black patients with AFib were 25% less likely to receive a prescription for oral anticoagulation at discharge and 27% less likely to receive a DOAC than their non-Hispanic White counterparts.
Preexisting Statin Use Linked to Lower COVID-19 Severity
October 24th 2022An analysis of electronic medical record data from more than 140k patients hospitalized at 185 medical centers in the US provides insight into associations between preexisting statin use and reduced risk of severe disease in COVID-19.
Study Details Gaps in Diagnosis for Homozygous Familial Hypercholesterolemia in the US
October 12th 2022An analysis of the CASCADE FH Registry provides insight into differences in patient characteristics and outcomes among those with homozygous familial hypercholesterolemia enrolled in the registry as children and those enrolled in the registry as adults.
Rethinking Statins: Time for Primordial Prevention?
September 27th 2022Statins and their specific role have been the subject of debate for years. In this feature, 6 leading experts in cardiometabolic health share their perspectives on whether statins should be used in the sense of primordial prevention for ASCVD.
Network Meta-Analysis Details Comparative Efficacy of Nonstatin Lipid-Lowering Agents
September 23rd 2022A meta-analysis of 48 randomized controlled trials provides clinicians with insight into the comparative efficacy profiles of multiple nonstatin LDL-lowering agents when added to maximally tolerated statin therapy.
Statin Muscle Symptom Risk Overblown, Does Not Outweigh CV Benefits, CTT Study Shows
August 29th 2022Results of a CTT meta-analysis from ESC Congress 22 detail the excess risk of muscle symptoms observed with statin therapy from more than 20 clinical trials assessing statins against placebo or less intensive statin therapy.
PANTHER: P2Y12 Monotherapy Bests Aspirin for Secondary Prevention in Coronary Artery Disease
August 29th 2022The PANTHER study, which was a meta-analysis of 7 RCTs comparing P2Y12 inhibitor monotherapy against aspirin for secondary prevention in CAD, suggests use of P2Y12 inhibitor monotherapy was associated with a 12% reduction in risk of the primary composite endpoint, with a 23% relative reduction in risk of myocardial infarction.
Milvexian Shows Promise for Preventing Stroke in Phase 2 Dose-Finding Trial
August 28th 2022A phase 2 dose-finding trial presented at ESC Congress 22 suggests the use of milvexian could reduce the risk of ischemic stroke by up to 30% without a major increase in the risk of bleeding events in certain doses.
Cardiology Month in Review: August 2022
August 27th 2022Our cardiology month in review spotlights the most popular content from the past month. The top content from August 2022 includes new antithrombotic guidance from CHEST, USPSTF recommendation statement on statin use in primary prevention, and coverage of ESC 22, including DELIVER, TIME, and other late-breaking data.
Modeling Study Sheds Light on Benefits on Lifelong Statin Therapy
August 25th 2022A modeling study presented at ESC 2022 provides insight into the differences in potential benefits of statin therapy based on lifelong use, delayed initiation, and early discontinuation among patients across the spectrum of cardiovascular risk.
USPSTF Reaffirms Endorsement for Statin Use in Primary Prevention Settings
August 23rd 2022The USPSTF released a new recommendation statement on August 23 outlining the organization's stance on use of statins for primary prevention based on current available evidence, with recommendations made for those 40-75, 75 and older, and based on 10-year CVD risk.
CHEST Releases New Guidance for Perioperative Management of Antithrombotic Therapy
August 12th 2022On August 11, the American College of Chest Physicians (CHEST) released 44 new evidence-based recommendations in their new guidelines for perioperative management of antithrombotic therapy, which were published with the intention of replacing the 2012 guidelines on the subject.
Ticagrelor Use Varies Greatly Between Hospitals, Even Without Added Cost Considerations
July 15th 2022After US-based data suggested cost as an inhibiting factor of ticagrelor use in older patients with ACS, an analysis of use in Canada details considerable variation in between-hospital levels of ticargelor, with use ranging from 0% to 83.6% of patients.
Most Stroke Patients Have Undiagnosed Major Risk Factors
June 28th 2022An analysis of data from a single center in Switzerland from a 15-year period details the prevalence of undiagnosed major risk factors among patients admitted with acute ischemic stroke, suggesting 67.7% present with at least 1 undiagnosed risk factor.
Statins Could Slow Progression of Arterial Stiffness in High-Risk Patients
June 20th 2022A retrospective analysis comparing statin users and nonusers details the significant declines in arterial stiffness progression among patients of high atherosclerotic risk based on statin use and adherence in a cohort of more than 5000 patients.
Rivaroxaban Bests Combination Therapy for Total Event, Mortality Risk in Stable CAD with AFib
June 16th 2022A secondary analysis of the AFIRE trial provides further detail on the reduction in event risk and mortality associated with rivaroxaban monotherapy compared to combination therapy in patients with atrial fibrillation and stable coronary artery disease.
Clopidogrel Tops Aspirin for Long-Term Antiplatelet Therapy After PCI in High-Risk Patients
May 20th 2022An analysis of data from the Fuwai PCI registry details the incidence of adverse events and risk of bleeding associated with clopidogrel monotherapy versus aspirin monotherapy 12 months post-PCI in high-risk patients.